EMA Clarifies Questions Over Biosimilar Interchangeability
Q&A Document Follows EMA-HMA Statement On Scientific Rationale Last Year
Responding to questions seeking clarifications over a statement on the scientific rationale supporting the interchangeability of biosimilars in the EU, the EMA has issued a supplementary Q&A document to address issues around multiple switches, complexity of molecular structure and national switching policies.
